GW joins a nationwide network of research centers in the Northeast ALS (NEALS) Consortium who are partnering with the Sean M HEALEY & AMG Center to conduct the first ALS platform trial. The platform trial is designed in a way that allows for testing multiple drugs simultaneously while reducing the amount of patients that receive placebo. The trail operates under a master protocol which outlines standard procedures that all drug regimens follow. Each drug that is being tested has its own regimen, which has a sub-protocol (under the master) that outlines procedures for that specific drug. Follow this link for more information on the platform trials.
Regimen F: ABBV-CLS-7262, follow this link for more information on Regimen F.
Regimens Closed to Enrollment:
Regimen E, Trehalose
Soon to be activated:
Regimen G: DNL 343, Follow this link for more information on Regimen G.
Regimen E Expanded Access Program: This trial is designed for patients not eligible for the other regimens OR who previously completed the Regimen E double blinded trial.
If you are interested or would like to learn more, please do not hesitate to reach out to our study coordinator, Grace Johnson at 202-741-2181 or firstname.lastname@example.org.